Retatrutide (LY3437943): The Triple-Agonist Evidence Base

Retatrutide, developed under the code LY3437943, is a synthetic peptide agonist at three receptors in the same molecule: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). The literature calls this a tri-agonist or triple-hormone-receptor agonist. All three receptors belong to the class B secretin-like family of G protein-coupled receptors, which is what makes a single-sequence ligand chemically feasible at all - the three native hormones share enough architecture that a peptide can be engineered to bind all of them.

This is a design lineage, not an isolated molecule. Semaglutide engages one of the three receptors, tirzepatide two, and retatrutide three. Each step was an attempt to recruit an additional metabolic pathway rather than to intensify an existing one, and each step made the pharmacology harder to reason about, because the receptors do not act in the same direction on every parameter.

The catalogue identity record for retatrutide carries CAS 2381089-83-2 but no PubChem CID, because PubChem does not resolve the compound by name. Analytical identity for any given material therefore rests on the lot certificate rather than on a public structural record - a practical point worth knowing when comparing reference material against published pharmacology.

The GLP-1 and GIP receptor arms of retatrutide follow familiar logic. GLP-1 receptor agonism produces glucose-dependent insulin secretion, slowed gastric emptying and central effects on appetite; GIP receptor agonism contributes an additional incretin effect and appears to modulate adipose tissue handling. Tirzepatide had already established that combining the two in one peptide was tractable.

The glucagon receptor is a different proposition. Glucagon signalling increases energy expenditure and promotes hepatic lipid oxidation - both attractive in an obesity context - but it also drives hepatic glucose production, which is precisely what a diabetes drug is meant to suppress. A tri-agonist therefore has to capture the energetic effect of glucagon receptor engagement while the incretin arms hold glycaemia in check. The relative potency at each of the three receptors is not incidental tuning; it is the entire design problem.

Coskun and colleagues characterised that balance in cell-based receptor assays and then tested it sequentially in rodent models before human dosing. The important interpretive point is that potency measured at a cloned receptor in a cell line does not translate linearly into tissue-level effect in an intact organism, and the authors treat the rodent and human phases as separate questions rather than as confirmation of the in vitro numbers. The published clinical results are the evidence that the balance holds in people; the in vitro work explains why it might.

Two Phase 2 trials published in 2023 define most of what is publicly known about retatrutide's effect size. Jastreboff and colleagues randomised adults with obesity and reported a mean body-weight reduction of approximately 24% from baseline at 48 weeks in the highest-dose group, against a small reduction on placebo. The figure attracted attention because it exceeded the published results for any single- or dual-receptor incretin agent at the time.

The detail that carries the most information is not the headline number but the shape of the curve: body weight was still declining when the trial ended. A 48-week result therefore describes an effect that had not yet reached its asymptote, which is a genuinely different statement from a plateau at the same value.

Rosenstock and colleagues ran the glycaemic counterpart in adults with type 2 diabetes, comparing retatrutide against both placebo and dulaglutide over 36 weeks. This trial directly addressed the concern that glucagon receptor agonism might undermine glucose control, and reported substantial HbA1c reductions in the higher-dose groups. Having an active comparator rather than placebo alone makes this the more informative of the two trials for judging where retatrutide sits relative to existing agents, even though it is the less-quoted one.

Both trials described gastrointestinal adverse events - nausea, vomiting, diarrhoea - as the most common findings, generally dose-related and concentrated during dose escalation. This is a class characteristic of incretin receptor agonists rather than something specific to the glucagon receptor arm.

Until recently, every widely circulated retatrutide figure came from trials enrolling a few hundred participants for under a year. That has begun to change. TRANSCEND-T2D-1, reported by Bajaj and colleagues, is a Phase 3 randomised trial in people with type 2 diabetes inadequately controlled with diet and exercise, and represents the first registrational-scale evidence to appear in the indexed literature.

The broader registrational effort is described in the TRIUMPH design paper by Giblin and colleagues. What is notable about the programme is its scope: rather than testing weight change alone, it extends into obstructive sleep apnea and knee osteoarthritis - conditions where obesity is a driver and where outcomes can be measured on instruments independent of the scale. Programmes designed this way generate claims that are harder to dispute later, and reading the protocol is the most reliable way to anticipate which claims will eventually be supportable.

None of this makes retatrutide an approved product. As of this monograph's date it remains investigational, with no marketing authorisation in Canada or the United States. Material supplied as a reference standard is not a medicine and is not a substitute for one.

The largest open question is durability. The Phase 2 trials ran for 36 and 48 weeks; obesity and type 2 diabetes are conditions measured in decades. Whether the effect is maintained, whether it attenuates, and what happens on discontinuation are questions the published retatrutide literature cannot yet answer, though the semaglutide and tirzepatide literature suggests weight regain after withdrawal is the expected pattern for the class.

Cardiovascular outcome data are absent. Semaglutide has SUSTAIN-6 and SELECT; retatrutide has nothing comparable published. Given that glucagon receptor agonism has haemodynamic consequences and that trials of incretin agents consistently report modest heart-rate increases, this is a specific gap rather than a formality.

Body composition is a third open area. Substantial weight loss from any mechanism includes lean mass, and the proportion matters more at the effect sizes retatrutide produces than at smaller ones. The published trials report body weight far more thoroughly than they report its composition. Finally, there is no published head-to-head trial against tirzepatide or semaglutide, so cross-trial comparisons - which differ in population, duration and escalation schedule - remain the only available basis for ranking these agents, and they are a weak one.